An interventional study of Acyclovir 400 MG and Ganciclovir (GCV) in Herpetic Keratitis, sponsored by Al-Azhar University. Completed at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2025-01-03.
Sponsored by Al-Azhar University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Traditional antiviral treatments, including systemic acyclovir, have shown effectiveness in resolving keratitis but can also lead to complications, including ocular surface toxicity and the development of acyclovir-resistant strains of HSV. Topical ganciclovir 0.15% ophthalmic gel presents a safer alternative for managing herpetic keratitis, offering effective viral suppression with minimal toxicity. This study aims to compare the efficacy and safety of topical ganciclovir versus systemic acyclovir in treating herpetic keratitis, providing valuable insights into optimal management strategies for this condition
Al-Azhar University is the lead sponsor of 535 studies on the registry; 173 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Ganciclovir (GCV)
Drug: Acyclovir 400 MG
Acyclovir is used to treat infections caused by certain types of viruses.
Ganciclovir is an anti-viral drug
Corneal healing
Heling of the keratitis
Time frame: At 4 and 6 weeks
Sie effects
Measuring the percentage of the side effects of the drugs
Time frame: at 4 and 6 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Oct 2024 to primary completion in Dec 2024, 2 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Acyclovir · Ganciclovir
Keratitis, Herpetic